Author

Kentaro Furukawa

National Institute of Biomedical Innovation, Health and NutritionPrimary ORCID profile (0000-0002-1551-1538 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Kentaro FurukawaiD1 paper · Kyushu University

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Haruhiko KamadaiD· 1 shared Haruyo Konishi· 1 shared Keita FukaoiD· 1 shared Mai YoshikawaiD· 1 shared Masaaki SatoiD· 1 shared Masahiro TakayamaiD· 1 shared Satoshi NagataiD· 1 shared Shinya Shano· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Haruhiko KamadaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo

Yoji Tsugawa, Kentaro Furukawa, Tomoko Ise, Masahiro Takayama, Takeshi Ota, Takayuki Kuroda, Shinya Shano, Takashi Hashimoto, Haruyo Konishi, Takeshi Ishihara, Masaaki Sato, Haruhiko Kamada, Keita Fukao, Takao Shishido, Mai Yoshikawa, , Satoshi Nagata

This study identifies an antibody, CV804, that targets the conserved S2 domain of coronaviruses and shows broad cross-reactivity and ADCC activity against SARS-CoV-2 and related viruses.

PLoS ONE · Dec 2, 2024Peer-reviewedMicrobiology